Urology Times staff

“After doing a literature review about cystectomy patients and how devastating it is for female sexual function after having a cystectomy, [my main takeaway from this study is that] it seems that women tolerate the intravesical treatments well,” says Talia A. Helman, MD.

"The most significant rate of burnout has increased in female urologists," says Marah C. Hehemann, MD.

"What we found [with] 78 patients [was] that patient satisfaction was the same whether you place it in the prevesical space or the ectopic space," says Mohit Khera, MD, MBA, MPH.

"This study is significant because it really emphasizes the importance of early detection of both BPH and ED, because knowing that information can really preserve men's quality of life," says Olivia Paulsen.

“Nowadays with PET, it's not perfect, but even with a PSA less than 1 ng/mL, we can detect the site of recurrence about 2/3 of the time,” says Bridget Koontz, MD.

"We found an increased association with AKI or acute kidney injury in the group receiving testosterone replacement therapy," said Evan Panken, MD.

Bajic summarizes his 2024 Sexual Medicine Society of North America Fall Scientific Meeting talk “Penile Prosthesis Biofilms: Friend or Foe?”

"What we found is that costs have really dramatically decreased year by year for all 3 medications," says Ellen Cahill, MD.

"You've got a double pronged attack to kill cancer cells, which is in line with our concepts of immunologic care and immunologic treatment in a variety of cancers, especially cancers such as bladder cancer," says Gary D. Steinberg, MD.

"I think patient preference is going to be the most important thing here," says Raevti Bole, MD.

"We're also dealing with some cultural biases, and we have to be mindful [of] how do people like to discuss sexual medicine, and how does that impact our patient interactions?" says Denise Asafu-Adjei, MD, MPH.

"Having a digital footprint is one of the most important things we can do as health care providers," says Amy Pearlman, MD.

"I think it's great, actually, that finally, we have more data on nutrition that we can recommend to our patients," says Stacy Loeb, MD, MSc, PhD (hon).

“Allowing these women to have a fulfilling life after cancer is one of the best things we can do as physicians,” says Talia A. Helman, MD.

"Looking at the survey results, we found that about 40% of men under the age of 40 are interested, at least, in supplementing their testosterone," says Justin Dubin, MD.

"We see [urinary incontinence] in up to 62% of US women, and we know that in women with incontinence, about 25% report that it negatively impacts their sexual health," says Ramzy T. Burns, MD.

"The TRAVERSE trial is the largest randomized placebo-controlled trial ever published in men receiving testosterone vs placebo," says Mohit Khera, MD, MBA, MPH.

"As with any drug, I think there's a big learning curve that comes anytime something's approved," says Landon Trost, MD.

“Particularly [in] bladder cancer, there's 2 new drugs on the market that are exceptionally expensive, but they do provide benefit to patients,” says Geoffrey N. Sklar, MD, FACS.

“So, this study is really getting at that question, could radiation target the lesions that we see on PET, and could we delay hormone therapy for men?” says Bridget Koontz, MD.

"This is a very exciting time for nuclear medicine and molecular medicine," says Jitesh Dhingra, MD, FRCEM.

"Aquablation can be used for small, medium, large, and extra-large prostates," says Ravi Munver, MD.

"Aquablation is like no other transurethral therapy that has come about in the last 100 years," says Ravi Munver, MD.

“So, we have all of this new technology that's about a year old, making surgery a lot safer for patients, making things more efficient, and [giving us] the ability to see stone removal happening from a perspective where we can visualize stone clearance in a way that we haven't been able to before,” says Marcelino E. Rivera, MD.

“We need to close that gap, and just as a general rule, screen our prostate cancer patients more closely for depression, especially those with androgen deprivation therapy,” says Mihir S. Shah, MD.

"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO.

"[Aquablation] is the only therapy that offers the benefits of a true resective therapy, which is what it is, as well as a non-resective therapy," says Ravi Munver, MD.

“We noticed that if you were White and had prostate cancer and received androgen deprivation therapy, you were more likely to be diagnosed with depression compared to your Black counterparts,” says Mihir S. Shah, MD.

"Aquablation is versatile. It can manage a very wide range of prostate sizes and shapes," says Stephen Overholser, MD.

"Both AR and neuroendocrine marker expressions in mCSPC patients at baseline is associated with worse prognosis," says Cedric Pobel, MD.